At the conclusion of this activity participants should be able to:

1. Review the data supporting the use of injectable extended-release buprenorphine treatment for opioid use disorder
2. Identify special risks that fentanyl use presents and the possible role of injectable extended release buprenorphine treatment.
3. Discuss the role of extended-release injectable buprenorphine in the treatment of OUD patients using fentanyl 

How to claim your credits & download handouts for each webinar:

1. Complete the required course materials.
2. Claim your credits by clicking the "Report Credit" or "Request Credit" button on the right above the course materials.

HPSO are the leading cause of overdose death in the US and minimal empiric data exist to guide treatment decisions. Attendees will be gain understanding of the pharmacology of HPSO, understand how current OUD pharmacotherapy interacts with HPSOs, and potential treatment options including long-acting injectable buprenorphine.

This webinar has been approved for 1 AOA Category 1-A CME credits, and AOA designates this for a maximum of 1 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of the extent of their participation. This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the American Osteopathic Association (AOA) and AOAAM. The AOA is accredited by the ACCME to provide continuing medical education for physicians.

Funding for this initiative was made possible (in part) by grant no. 1H79TI083343 from SAMHSA. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.